Catridecacog
Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Catridecacog
Catridecacog, sold under the brand name Tretten in the US and NovoThirteen in the EU) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014. It was brought to market by Novo Nordisk.
has abstract
Catridecacog, sold under the b ...... ght to market by Novo Nordisk.
@en
alternative name
Tretten, NovoThirteen
@en
CAS number
606138-08-3
ChEMBL
DrugBank
FDA UNII code
NU23Q531G1
KEGG
Link from a Wikipage to an external page
Wikipage page ID
41,867,774
page length (characters) of wiki page
Wikipage revision ID
1,012,803,138
Link from a Wikipage to another Wikipage
ATC prefix
B02
@en
ATC suffix
BD11
@en
CAS number
ChEMBL
ChemSpiderID
none
@en
DailyMedID
Catridecacog
@en
DrugBank
DB09310
@en
KEGG
D10532
@en
legal AU
Unscheduled
@en
legal EU
Rx-only
@en
legal US
Rx-only
@en
licence EU
yes
@en
pregnancy AU
B2
@en
pregnancy US
N
@en
routes of administration
Injection
@en
tradename
Tretten, NovoThirteen
@en
UNII
NU23Q531G1
@en
wikiPageUsesTemplate
hypernym
comment
Catridecacog, sold under the b ...... ght to market by Novo Nordisk.
@en
label
Catridecacog
@en